Cipla surges on getting nod to invest upto $100 million in Cipla (EU)
The board at its meeting held on March 19, 2026 has approved the same
Cipla is currently trading at Rs. 1263.00, up by 24.35 points or 1.97% from its previous closing of Rs. 1238.65 on the BSE.
The scrip opened at Rs. 1248.65 and has touched a high and low of Rs. 1264.00 and Rs. 1248.65 respectively. So far 5645 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1672.20 on 23-Oct-2025 and a 52 week low of Rs. 1,242.65 on 19-Mar-2026.
Last one week high and low of the scrip stood at Rs. 1327.85 and Rs. 1242.65 respectively. The current market cap of the company is Rs. 102018.91 crore.
The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.64% and 16.14% respectively.
Cipla has received approval from board of directors for investment upto $100 million in the equity share capital of Cipla (EU), a wholly- owned subsidiary of the Company for the purpose of providing onward financial assistance to InvaGen Pharmaceuticals Inc., wholly-owned subsidiary of Cipla (EU), to meet its capital expenditure, working capital requirements and other general corporate purposes.
The board at its meeting held on March 19, 2026 has approved the same.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
